Novo Nordisk Shares Plunge More Than 10% Premarket After ZEUS Phase III Update
CLS reported on July 31 that Novo Nordisk shares plunged more than 10% in U.S. premarket trading after the company released the latest update on its ZEUS Phase III clinical trial.
CLS reported on July 31 that Novo Nordisk shares plunged more than 10% in U.S. premarket trading after the company released the latest update on its ZEUS Phase III clinical trial.